LHDX - Lucira stock surges ~20% on FDA filing for OTC use of COVID flu test
- Lucira Health ( NASDAQ: LHDX ) said it submitted an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for OTC use of its at-home molecular COVID-19 & Flu test.
- Lucira noted that its test for COVID & Flu was granted EUA for point-of-care (POC) use in a healthcare setting in November 2022.
- Lucira plans to make the test available online and in pharmacies. The company added that it worked with the FDA to complete additional testing to show that the test could be used by consumers at home.
- LHDX +23.49% to $0.14 premarket Jan. 3
For further details see:
Lucira stock surges ~20% on FDA filing for OTC use of COVID, flu test